6White H, Sosnowski K, Bird R, et al. The utility of thromboelastography in monitoring low molecular weight heparin therapy in the coronary care unit [ J ]. Blood Coagul Fibrinolysis, 2012,23 ( 4 ) : 304-310.
7Van PY, Cho SD, Underwood SJ, et al. Thrombelasto- graphy versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients [J]. J Trauma, 2009, 66(6) :1509-1515.
8Al Dieri R, Alban S, Bguin S, et al. Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight[J]. J Thromb Haemost, 2006, 4( 1 ) :83- 89.
9Kovacs M J, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin [ J ]. Circulation, 2004,110 ( 12 ) : 1658-1663.
10Barras MA, Duffull SB, Atherton JJ, et al. Individualized compared with conventional dosing of enoxaparin[ J ]. Clin Pharmacol Ther, 2008, 83 (6) : 882-888.
